There are 2789 resources available
1432P - Characterizing diversity in the immune profile by a transcriptomic customized gene signature to potentially personalize treatment in advanced gastric cancer patients
Presenter: Manuel Cabeza-Segura
Session: ePoster Display
1433P - Esophageal cancer cell dynamics significantly depended on blood cell circuit, biochemical factors, hemostasis system, cancer characteristics and anthropometric data
Presenter: Oleg Kshivets
Session: ePoster Display
1434TiP - MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
Presenter: Daniel Catenacci
Session: ePoster Display
1435TiP - Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial
Presenter: Xiaozheng Kang
Session: ePoster Display
1436TiP - Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study
Presenter: Kohei Shitara
Session: ePoster Display
1362TiP - Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: The GeoMETry-III phase III study
Presenter: Pierre-Jean Souquet
Session: ePoster Display
1363TiP - A phase I/II study of TPX-0131, a novel oral ALK tyrosine kinase inhibitor, in patients with ALK+ advanced/metastatic NSCLC
Presenter: Ben Solomon
Session: ePoster Display
1364TiP - Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy
Presenter: Byoung Chul Cho
Session: ePoster Display
1365TiP - A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy
Presenter: Sun Min Lim
Session: ePoster Display